Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies.
CONCLUSION: Carfilzomib has a favorable benefit-risk profile in MM; adopting proactive practices can assist in the prevention, early detection, and management of carfilzomib-associated cardiovascular events, which may allow for continuation of therapy with this effective agent.
PMID: 28545322 [PubMed - as supplied by publisher]
Source: Hematology - Category: Hematology Tags: Hematology Source Type: research
More News: Cardiology | Cardiovascular | Education | Heart | Hematology | Myeloma | Study | Toxicology | Universities & Medical Training | Velcade